Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.53, $0.26 better than the analyst estimate of $0.27. Revenue for the quarter came in at $110.57 million versus the consensus estimate of $106.13 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.